Early detection of at-risk patients of re-presentation to emergency department using a recurrent neural network (Preprint)

2021 ◽  
Author(s):  
Euijoon Ahn ◽  
Tanya Baldacchino ◽  
Rod Hughes ◽  
Christine Baird ◽  
Jinman Kim

BACKGROUND Re-presentations to emergency departments (EDs) have been directly associated with increased healthcare cost and length of stay, poorer quality of care and increased morbidity and mortality. Early detection of at-risk patients to EDs can reduce unnecessary re-presentations and provide provision of better quality of care and healthcare planning. Conventional risk predictive models, however, have difficulties when the at-risk patients have diverse and complex disease states or demographic profiles. These models also ignore related temporal patient information such as changes in their disease state and personal circumstance which can be used to model the progression of risks. OBJECTIVE Our aim is to develop a temporal risk predictive model based on recurrent neural network (RNN) can understand temporal relationships between different times of patient presentations to EDs and improve the predictive modelling. METHODS We used the data extracted from Health Information Exchange (HIE) system, which included all available ED records from the Nepean hospital in Australia from the period 1 January 2009 to 30 June 2016. A total of 343,014 ED presentations were identified from 170,134 individual patients. We used the variables including age, marital status, indigenous status, mode of arrival, mode of separations, referred to on departure and diagnosis code which have shown to be correlated to frequent presenters to EDs. We evaluated our RNN model by comparing it to other conventional predictive models using the area under to receiver operating characteristics curve (AUROC). All models were trained using the ED data extracted from the 6 to 12-months period by setting an interval that is divided into an observation window and a prediction window. We further proposed a context-based patient representation learning (CPRL) framework to better characterise the feature representation of patient data and discussed the general extension of our CPRL framework as an optimisation algorithm to improve the feature representation of patient data. RESULTS Using a 9-month observation with 1-month prediction window (i.e., prediction of at-risk patients of re-presentation to ED in next 1-month), the AUROC for the RNN model was 71.60% compared to AUROCs for logistic regression (57.18%), Naves Bayes (56.35%) and random forest (56.02%). The at-risk patients presented to the ED more frequently (i.e., time (day) differences between presentations become shorter) when their marital status was changed (e.g., from ‘Married’ to ‘Separated’ or ‘Separated’ to ‘Divorced’). These patients also consistently had similar diagnoses during the observation period, indicating that these groups of patients may be the focus of certain integrated cares / interventions to improve the quality of care and reduce the unnecessary re-presentations. CONCLUSIONS Our findings indicate that our RNN improves the predictive modelling, is robust and can effectively understand the disease state and personal circumstance changes within patients over time. We suggest that our model highlights the gaps in ED interventions and can be used to develop tailored integrated cares / interventions.

2021 ◽  
pp. flgastro-2020-101713
Author(s):  
Mathuri Sivakumar ◽  
Akash Gandhi ◽  
Eathar Shakweh ◽  
Yu Meng Li ◽  
Niloufar Safinia ◽  
...  

ObjectivePrimary biliary cholangitis (PBC) is a progressive, autoimmune, cholestatic liver disease affecting approximately 15 000 individuals in the UK. Updated guidelines for the management of PBC were published by The European Association for the Study of the Liver (EASL) in 2017. We report on the first national, pilot audit that assesses the quality of care and adherence to guidelines.DesignData were collected from 11 National Health Service hospitals in England, Wales and Scotland between 2017 and 2020. Data on patient demographics, ursodeoxycholic acid (UDCA) dosing and key guideline recommendations were captured from medical records. Results from each hospital were evaluated for target achievement and underwent χ2 analysis for variation in performance between trusts.Results790 patients’ medical records were reviewed. The data demonstrated that the majority of hospitals did not meet all of the recommended EASL standards. Standards with the lowest likelihood of being met were identified as optimal UDCA dosing, assessment of bone density and assessment of clinical symptoms (pruritus and fatigue). Significant variations in meeting these three standards were observed across UK, in addition to assessment of biochemical response to UDCA (all p<0.0001) and assessment of transplant eligibility in high-risk patients (p=0.0297).ConclusionOur findings identify a broad-based deficiency in ‘real-world’ PBC care, suggesting the need for an intervention to improve guideline adherence, ultimately improving patient outcomes. We developed the PBC Review tool and recommend its incorporation into clinical practice. As the first audit of its kind, it will be used to inform a future wide-scale reaudit.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 696.2-696
Author(s):  
G. Abignano ◽  
D. Temiz Karadağ ◽  
O. Gundogdu ◽  
G. Lettieri ◽  
M. C. Padula ◽  
...  

Background:The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that 82% of patients with Raynaud’s Phenomenon, specific ANA positivity and scleroderma pattern at nail fold videocapillaroscopy will fulfil classification criteria within 5 years. This is suggesting that there is a subclinical window of opportunity to diagnose systemic sclerosis (SSc) before clinical manifestations occur. In this scenario, a non-invasive tool to diagnose SSc in clinically unaffected skin might improve the early detection of disease in at risk-patients. Optical coherence tomography (OCT) of the skin has been shown to be a sensitive and accurate biomarker of skin fibrosis in SSc.Objectives:Here we aimed to assess the ability of skin OCT to “detect” SSc in clinically unaffected skin from a multicentre cohort.Methods:Dorsal forearm skin of SSc patients and matched-healthy controls (HC) was evaluated using VivoSight scanner (Michelson Diagnostics). Mean A-scans (mean OCT signal plotted against depth-in-tissue) were derived as previously described. Minimum Optical Density (MinOD), Maximum OD (MaxOD) and OD at 300 micron-depth (OD300) were calculated. Clinical involvement was assessed by an operator blinded to OCT findings using the mRSS. Receiver-operating characteristic (ROC) curve analysis was carried out for MinOD, MaxOD, and OD300 to evaluate their ability to discriminate between SSc and HC. Statistical analysis was performed using GraphPad Prism software V.7.0.Results:One hundred seventy four OCT images were collected from 87 subjects [43 SSc (39 Female, mean age 49.7±9.1 years) and 44 gender/age-matched healthy controls (HC) (36 Female, mean age 50.2±8.3 years)] in two different SSc centres. All patients fulfilled classification criteria for SSc. OCT measures demonstrated discriminative ability in SSc skin detection with any clinical skin involvement (0-3 at site of analysis) with an AUC of 0.73 (MinOD, 95%CI 0.64-0.81), 0.77 (MaxOD, 95%CI 0.7-0.85) and 0.82 (OD300, 95%CI 0.76-0.89); p<0.0001 for all as previously indicated. Most importantly, all three measures showed comparable performance in detecting scleroderma also in clinically unaffected skin (mRss=0 at site of analysis), with an AUC of 0.7 (95%CI 0.6-0.81, p=0.001), 0.72 (95%CI 0.61-0.83, p=0.0003) and 0.72 (95%CI 0.61-0.83, p=0.0003) for MinOD, MaxOD and OD300 respectively.Conclusion:Virtual biopsy by OCT recognises clinically unaffected skin of SSc patients from the HC skin. This is consistent with gene array data showing that scleroderma specific signatures are consistent in affected and clinically unaffected skin. These results inform future studies on at risk patients with clinically unaffected skin which may define a role for OCT in detecting subclinical SSc.Disclosure of Interests:Giuseppina Abignano: None declared, Duygu Temiz Karadağ: None declared, Ozcan Gundogdu: None declared, Giovanni Lettieri: None declared, Maria Carmela Padula: None declared, Angela Padula: None declared, Paul Emery Grant/research support from: AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche (all paid to employer), Consultant of: AbbVie (consultant, clinical trials, advisor), Bristol-Myers Squibb (consultant, clinical trials, advisor), Lilly (clinical trials, advisor), Merck Sharp & Dohme (consultant, clinical trials, advisor), Novartis (consultant, clinical trials, advisor), Pfizer (consultant, clinical trials, advisor), Roche (consultant, clinical trials, advisor), Samsung (clinical trials, advisor), Sandoz (clinical trials, advisor), UCB (consultant, clinical trials, advisor), Salvatore D’Angelo: None declared, Francesco Del Galdo: None declared


Author(s):  
Aaron Dora‐Laskey ◽  
Joan Kellenberg ◽  
Chin Hwa Dahlem ◽  
Elizabeth English ◽  
Monica Gonzalez Walker ◽  
...  

2019 ◽  
Vol 49 (13) ◽  
pp. 2134-2140 ◽  
Author(s):  
Steffen Moritz ◽  
Łukasz Gawęda ◽  
Andreas Heinz ◽  
Jürgen Gallinat

AbstractSince the 1990s, facilities for individuals at putative risk for psychosis have mushroomed and within a very short time have become part of the standard psychiatric infrastructure in many countries. The idea of preventing a severe mental disorder before its exacerbation is laudable, and early data indeed strongly suggested that the sooner the intervention, the better the outcome. In this paper, the authors provide four reasons why they think that early detection or prodromal facilities should be renamed and their treatment targets reconsidered. First, the association between the duration of untreated psychosis and outcome is empirically established but has become increasingly weak over the years. Moreover, its applicability to those who are considered at risk remains elusive. Second, instruments designed to identify future psychosis are prone to many biases that are not yet sufficiently controlled. None of these instruments allows an even remotely precise prognosis. Third, the rate of transition to psychosis in at-risk patients is likely lower than initially thought, and evidence for the success of early intervention in preventing future psychosis is promising but still equivocal. Perhaps most importantly, the treatment is not hope-oriented. Patients are more or less told that schizophrenia is looming over them, which may stigmatize individuals who will never, in fact, develop psychosis. In addition self-stigma has been associated with suicidality and depression. The authors recommend that treatment of help-seeking individuals with mental problems but no established diagnosis should be need-based, and the risk of psychosis should be de-emphasized as it is only one of many possible outcomes, including full remission. Prodromal clinics should not be abolished but should be renamed and restructured. Such clinics exist, but the transformation process needs to be facilitated.


2001 ◽  
Vol 161 (12) ◽  
pp. 1549 ◽  
Author(s):  
Courtney H. Lyder ◽  
Jeanette Preston ◽  
Jacqueline N. Grady ◽  
Jeanne Scinto ◽  
Richard Allman ◽  
...  

BMJ ◽  
2013 ◽  
Vol 346 (feb13 4) ◽  
pp. f982-f982 ◽  
Author(s):  
A. Cole
Keyword(s):  
At Risk ◽  

2003 ◽  
Vol 19 (1) ◽  
pp. 287-295 ◽  
Author(s):  
Leticia Krauss Silva

This paper focuses on the issue of the extent to which the present mainstream risk adjustment (RA) methodology for measuring outcomes is a valid and useful tool for quality-improvement activities. The method's predictive and attributional validity are discussed, considering the confounding and effect modification produced by medical care over risk variables' effect. For this purpose, the sufficient-cause model and the counterfactual approach to effect and interaction are tentatively applied to the relationships between risk (prognostic) variables, medical technology, and quality of care. The main conclusions are that quality of care modifies the antagonistic interaction between medical technologies and risk variables, related to different types of responders, as well as the confounding of the effect of risk variables produced by related medical technologies. Thus, confounding of risk factors in the RA method, which limits the latter's predictive validity, is related to the efficacy and complexity of associated medical technologies and to the quality mix of services. Attributional validity depends on the validity of the probabilities estimated for each subgroup of risk (predictive validity) and the percentage of higher-risk patients at each service.


Sign in / Sign up

Export Citation Format

Share Document